Case Report: Concurrent breast myeloid sarcoma and ductal carcinoma in situ—multimodality imaging findings and differential treatment response
Abstract
Myeloid sarcoma (MS) is an uncommon extramedullary manifestation of myeloid neoplasms, and breast involvement is rare. We report concurrent breast MS and ductal carcinoma in situ (DCIS) in a 49-year-old woman who was referred for evaluation of cervical lymphadenopathy and subsequently underwent breast imaging for a rapidly enlarging palpable left breast mass. Mammography and ultrasonography showed a dominant noncalcified mass and separate calcification-associated lesions in the outer breast. Site-specific core biopsies identified MS in the noncalcified mass and concurrent MS and high-grade DCIS in a calcification-associated mass; an axillary lymph node also showed MS. Subsequent hematologic evaluation demonstrated BCR-ABL1-positive chronic myeloid leukemia (CML) with 3.5% bone marrow blasts, with extramedullary MS establishing blast-phase disease. MRI and FDG PET/CT performed after pathologic diagnosis demonstrated the extent of breast and extramammary disease. Approximately 5 weeks after initiation of systemic therapy, the enhancing breast lesions had markedly decreased on MRI. On follow-up ultrasonography, the mass component of the mixed MS and DCIS lesion also decreased, whereas the associated calcifications persisted. Mastectomy subsequently demonstrated residual DCIS without residual MS. Recognition of the different imaging patterns allowed separate sampling of morphologically distinct lesions and diagnosis of the two coexisting pathologic processes. Follow-up multimodality imaging demonstrated their different treatment responses.
Related
- Case Report: Long term multimodality treatment of canine hepatocellular carcinoma with serial monitoring of serum alpha-fetoprotein.
- Presumed hepatic pseudolipoma detected as a small hepatic surface lesion: multimodality imaging findings
- Primary gastric tuberculosis mimicking gastric lymphoma: a case report and multimodality imaging findings.
- A solitary brain metastasis from gastroesophageal junction adenocarcinoma 13 years after curative multimodality treatment: a case report and review of the literature
- Post-Recurrence Treatment Patterns and Outcomes After Curative-Intent Multimodality Strategy in Patients with Pleural Mesothelioma: A Retrospective Cohort Study
BibTeX
@article{kang2026case,
title = {{Case Report: Concurrent breast myeloid sarcoma and ductal carcinoma in situ—multimodality imaging findings and differential treatment response}},
author = {Chungpill Kang and Hye Young Choi and Ho Cheol Choi and Mi Jung Park and Ji Eun Kim and Hwa Seon Shin and Jung Ho Won and Seok Jin Hong and Jong-Sil Lee and Gyeong-Won Lee},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1996921},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1996921},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Concurrent breast myeloid sarcoma and ductal carcinoma in situ—multimodality imaging findings and differential treatment response
AU - Chungpill Kang
AU - Hye Young Choi
AU - Ho Cheol Choi
AU - Mi Jung Park
AU - Ji Eun Kim
AU - Hwa Seon Shin
AU - Jung Ho Won
AU - Seok Jin Hong
AU - Jong-Sil Lee
AU - Gyeong-Won Lee
PY - 2026
DA - 2026/11/06
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1996921
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1996921
AB - Myeloid sarcoma (MS) is an uncommon extramedullary manifestation of myeloid neoplasms, and breast involvement is rare. We report concurrent breast MS and ductal carcinoma in situ (DCIS) in a 49-year-old woman who was referred for evaluation of cervical lymphadenopathy and subsequently underwent breast imaging for a rapidly enlarging palpable left breast mass. Mammography and ultrasonography showed a dominant noncalcified mass and separate calcification-associated lesions in the outer breast. Site-specific core biopsies identified MS in the noncalcified mass and concurrent MS and high-grade DCIS in a calcification-associated mass; an axillary lymph node also showed MS. Subsequent hematologic evaluation demonstrated BCR-ABL1-positive chronic myeloid leukemia (CML) with 3.5% bone marrow blasts, with extramedullary MS establishing blast-phase disease. MRI and FDG PET/CT performed after pathologic diagnosis demonstrated the extent of breast and extramammary disease. Approximately 5 weeks after initiation of systemic therapy, the enhancing breast lesions had markedly decreased on MRI. On follow-up ultrasonography, the mass component of the mixed MS and DCIS lesion also decreased, whereas the associated calcifications persisted. Mastectomy subsequently demonstrated residual DCIS without residual MS. Recognition of the different imaging patterns allowed separate sampling of morphologically distinct lesions and diagnosis of the two coexisting pathologic processes. Follow-up multimodality imaging demonstrated their different treatment responses.
SN - 2234-943X
ER -